<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03821038</url>
  </required_header>
  <id_info>
    <org_study_id>IRIS-7-C&amp;D</org_study_id>
    <nct_id>NCT03821038</nct_id>
  </id_info>
  <brief_title>Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients</brief_title>
  <acronym>IRIS-7-C&amp;D</acronym>
  <official_title>International, Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts (ALC) in Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Revimmune</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Clinical Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Revimmune</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II randomized study will assess the effect of receiving IV recombinant human IL-7
      (CYT107) versus placebo in lymphopenic sepsis patients

      The aim is to confirm the immune cell reconstitution observed in other studies and other
      patient populations among which the IRIS-7 A&amp;B study which was conducted in the same patient
      population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphopenic sepsis Patients will be randomized 3:1 to receive either:

      a) Intravenous (IV) administration of CYT107 at 10 μg/kg twice a week for 3 weeks or b) IV
      placebo (normal saline).

      The effect of CYT107 on Lymphocyte and various T cell populations will be documented with a
      focus on the first 29 days.

      Stopping rules will apply if ALC increases to &gt;2.5 times the upper limit of normal range.

      The IRIS-7C &amp; D studies will be conducted at multiple sites in France and the United States.
      All sites will use the same study design and similar study protocol for a common statistical
      analysis of 40 evaluable participants.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>International, multicenter, randomized, double-blinded placebo- controlled</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Open-label pharmacist will prepare masked syringes for the ICU</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Lymphocyte reconstitution</measure>
    <time_frame>day 29 versus baseline</time_frame>
    <description>Change in absolute lymphocyte count (ALC) of ≥ 50%. If this 50% increase over baseline is reached in the placebo group due to natural immune reconstitution, then the day 29 percent increase of ALC over baseline will be compared between the two groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>90 days after study treatment initiation</time_frame>
    <description>Incidence and scoring of all grade 3-4 adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Infections</measure>
    <time_frame>within 90 days after treatment initiation</time_frame>
    <description>Incidence of secondary infections based on pre-specified criteria as adjudicated by the Secondary Infections Committee (SIC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in the ICU</measure>
    <time_frame>within 90 days after treatment initiation</time_frame>
    <description>Number of days in ICU following study treatment initiation during the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>readmissions to the ICU</measure>
    <time_frame>within 90 days after treatment initiation</time_frame>
    <description>Number of readmissions to ICU following study treatment initiation during index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>organ support free days</measure>
    <time_frame>within 90 days after treatment initiation</time_frame>
    <description>Number of organ support free days (OSFDs) following study treatment initiation during the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>re-hospitalization</measure>
    <time_frame>within 90 days following study treatment initiation</time_frame>
    <description>the incidence of re-hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>90 days after study treatment initiation</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell reconstitution</measure>
    <time_frame>through day 90</time_frame>
    <description>Absolute numbers of CD4+ and CD8+T-cell counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients reaching normal ALC</measure>
    <time_frame>through day 90</time_frame>
    <description>Percentage of patients reaching absolute lymphocyte counts (ALC) &gt; 1200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of IL-7 receptor</measure>
    <time_frame>through day 90</time_frame>
    <description>Effects on soluble and cellular IL-7 receptor (CD127) expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantification of HLA-DR on monocytes</measure>
    <time_frame>through day 90</time_frame>
    <description>Effects on circulating monocyte HLA-DR expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of IL-6 blood levels</measure>
    <time_frame>through day 90</time_frame>
    <description>Effects on whole blood circulating cytokines IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of IL-10 blood levels</measure>
    <time_frame>through day 90</time_frame>
    <description>Effects on whole blood circulating IL-10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of TNF-α blood levels</measure>
    <time_frame>through day 90</time_frame>
    <description>Effects on whole blood circulating TNF-α</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 Pharmacokinetic Tmax</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>determination of Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 Pharmacokinetic Cmax</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>determination of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 Pharmacokinetic half life</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>determination of half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 Pharmacokinetic clearance</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>determination of clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CYT107 Pharmacokinetic area under curve</measure>
    <time_frame>Day 1 and Day 15</time_frame>
    <description>determination of area under curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>anti-CYT107 antibodies</measure>
    <time_frame>day 1, day 29 or hospital discharge, day 90 and day 180 if previous sample positive</time_frame>
    <description>Quantification of circulating anti-CYT107 antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Sepsis, Severe</condition>
  <arm_group>
    <arm_group_label>CYT107</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous (IV) administration of CYT107 at 10 μg/kg twice a week for 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intravenous (IV) administration of the same volume of NaCl 0.9% twice a week for 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYT107</intervention_name>
    <description>IV twice a week at 10µg/kg for 3 weeks</description>
    <arm_group_label>CYT107</arm_group_label>
    <other_name>human recombinant glycosylated Interleukin-7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>IV twice a week at the same volume for 3 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A written, signed informed consent, by the patient or the patient's legally authorized
             representative

          2. Participants with an absolute lymphocyte count (ALC) ≤ 900 cells/mm3, at two time
             points at least twelve hours apart, following diagnosis of vasopressor dependent
             sepsis and,

               1. the second time point should not be performed earlier than 48 hours after sepsis
                  diagnosis,

               2. study drug treatment initiation is required no later than 120 hours (up to 5
                  days) after the last qualifying ALC ≤ 900 cells/mm3 measure, and

               3. the average value of the two qualifying ALC counts will serve as a baseline to
                  express the percent increase at day 29, or at hospital discharge.

          3. Patients in the ICU with onset of vasopressor dependent sepsis defined as hypotension
             requiring treatment with any vasopressor(s) for at least 6 hours to maintain a
             systolic pressure ≥ 90 mmHg or a mean arterial pressure ≥65 mmHg AND at least 1 of the
             2 organ dysfunction criteria below:

               1. Acute respiratory failure defined as the need for invasive mechanical ventilation
                  for at least 24 hours to support pulmonary function

               2. Acute kidney injury defined as creatinine &gt; 2.0 mg/dL (based on new abnormal
                  result following onset of sepsis) OR urine output &lt; 0.5 mL/kg/hr for &gt; 4 hours
                  despite adequate fluid resuscitation. In the presence of pre-existing impairment
                  of renal function (defined as a serum creatinine concentration &gt;2 times the upper
                  limit of the normal reference range prior to the onset of sepsis), the patient
                  must meet the other organ dysfunction criteria.

          4. Anticipated hospital duration of up to approx. three weeks after initiating study drug
             treatment to allow 6 study drug administrations (Days 18 or 19 would be final dose)

          5. This study permits the re-enrollment of a participant who may have been discontinued
             as a pre-treatment screen failure and/or prior to study drug treatment.

          6. Age and reproductive status:

               1. Women of childbearing potential (WOCBP) must have a negative serum or urine
                  pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24
                  hours prior to the start of study treatment

               2. Women must not be breastfeeding

               3. Women of childbearing potential (WOCBP) must agree to follow instructions for
                  method(s) of contraception for the duration of treatment with CYT107 plus 5
                  half-lives of CYT107 (the terminal half-life of CYT107 is up to 2 days) plus 30
                  days (duration of ovulatory cycle) for a total of 2 months post-treatment
                  completion.

               4. Males who are sexually active with WOCBP must agree to follow instructions for
                  method(s) of contraception for the duration of treatment with CYT107 plus 5
                  half-lives of CYT107 plus 90 days (duration of sperm turnover) for a total of 7
                  months post-treatment completion. In addition, male participants must be willing
                  to refrain from sperm donation during this time.

               5. Azoospermic males are exempt from contraceptive requirements.

               6. WOCBP who are continuously not heterosexually active are also exempt from
                  contraceptive requirements but still must undergo pregnancy testing.

        Exclusion Criteria:

          1. Cancer with current chemotherapy or radiotherapy (receipt of chemotherapy or
             radiotherapy for cancer within the last 6 weeks). All patients with current, or
             history of, hematologic malignancy (including, but not limited to, ALL, AML, CLL, CML,
             etc.) or lymphoma will be excluded, regardless of receipt of recent chemotherapy

          2. Patients with minimal chance of survival and life expectancy less than 3-5 days as
             defined by an APACHE II score of ≥ 35 at time of consideration for study eligibility

          3. Patients with history or current evidence of autoimmune disease including for example:
             myasthenia gravis, Guillain Barre syndrome, systemic lupus erythematosus, multiple
             sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis,
             Wegener's etc.

          4. Patients who have received a solid organ transplant or bone marrow transplant.

          5. Patients with active or a history of acute or chronic lymphocytic leukemia

          6. AIDS-defining illness (category C) diagnosed within the last 12 months prior to study
             entry

          7. Known history of chronic HBV infection and not on treatment with HBV nucleoside
             analogues prior to the current hospitalization or HBV DNA &gt; 100 IU/mL

          8. Known history of infection with HCV and currently undergoing treatment for HCV
             infections or has detectable HCV RNA

          9. Known history of tuberculosis and currently undergoing treatment for tuberculosis

         10. History of splenectomy

         11. Any hematologic disease associated with hypersplenism, such as thalassemia, hereditary
             spherocytosis, Gaucher's Disease, and autoimmune hemolytic anemia

         12. Participation in another investigational interventional study testing a drug or a
             medical device within the last 3 months prior to study entry

         13. Patients receiving immunosuppressive drugs, e.g., TNF-alpha inhibitors, for any
             reason, or systemic corticosteroids other than hydrocortisone at a dose of 300 mg/day

         14. Patients receiving concurrent immunotherapy or biologic agents; including growth
             factors, cytokines and interleukins other than the study medication : IL-2,
             Interferons α, β and γ, GM-CSF, G-CSF, HIV vaccines, immunosuppressive drugs,
             hydroxyurea, immunoglobulins, adoptive cell therapy

         15. Prior exposure to IL 7 or other drugs specifically targeting T cells

         16. Presence of an advanced directive to withhold or withdraw life-sustaining treatment,
             DNR order or no CPR order, or comfort measures only order

         17. Patients for whom prognosis is poor and source control of septic event is considered
             unlikely per the clinical and research teams.

         18. Patients under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Hotchkiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruno François, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Limoges Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michel MORRE, DVM</last_name>
    <phone>+33603357060</phone>
    <email>mmorre@revimmune.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane BLOOD, CRN</last_name>
    <phone>314-747-5531</phone>
    <email>bloodj@anest.wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Brakenridge, MD</last_name>
      <phone>352-273-5670</phone>
      <email>Scott.Brakenridge@surgery.ufl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Lanz, RN, ARNP</last_name>
      <phone>3522735497</phone>
      <email>Jennifer.Lanz@surgery.ufl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Hotchkiss, MD</last_name>
      <phone>314-362-8552</phone>
      <email>richardshotchkiss@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jane Blood, RN,BS</last_name>
      <phone>314-747-5531</phone>
      <email>jblood@wustl.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre ASFAR, MD</last_name>
      <phone>02.41.35.38.15</phone>
      <email>PiAsfar@chu-angers.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marc PIERROT, MD</last_name>
      <phone>0033 2.41.35.38.45</phone>
      <email>mapierrot@chu-angers.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital HENRI MONDOR</name>
      <address>
        <city>Créteil</city>
        <zip>94300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas DE PROST, MD</last_name>
      <phone>33149812394</phone>
      <email>nicolas.de-prost@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Armand MEKONTSO DESSAP, MD</last_name>
      <phone>33149812391</phone>
      <email>armand.dessap@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Pierre QUENOT, MD</last_name>
      <phone>03 80 28 13 03</phone>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pascal ANDREU, MD</last_name>
      <phone>03 80 28 13 03</phone>
      <email>pascal.andreu@chu-dijon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospital of Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno FRANCOIS, MD</last_name>
      <phone>33 (0)5 55 05 62 74</phone>
      <email>bruno.francois@chu-limoges.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Daix, MD</last_name>
      <phone>33 (0)5 55 05 62 74</phone>
      <email>thomas.daix@chu-limoges.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas RIMMELE, MD</last_name>
      <phone>33472111196</phone>
      <phone_ext>33472111196</phone_ext>
      <email>thomas.rimmele@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-François CARABALONA, MD</last_name>
      <phone>33472111196</phone>
      <phone_ext>33472111196</phone_ext>
      <email>jean-francois.carabalona@chu-lyon.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chr Orleans</name>
      <address>
        <city>Orleans</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
      <phone>0033 238514446</phone>
      <email>thierry.boulain@chr-orleans.fr</email>
    </contact>
    <contact_backup>
      <last_name>Mai-Anh NAY, MD</last_name>
      <phone>0033 238514446</phone>
      <email>mai-anh.nay@chr-orleans.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hopital COCHIN</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Paul MIRA, MD</last_name>
      <phone>33 (1) 58 41 25 17</phone>
      <email>jean-paul.mira@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Paul JAUBERT, MD</last_name>
      <phone>33 (1) 58 41 25 17</phone>
      <email>paul.jaubert@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Chru Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Francois DEQUIN, MD</last_name>
      <phone>02-47-47-38-55</phone>
      <email>pierre-francois.dequin@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Antoine GUILLON, MD</last_name>
      <phone>02-47-47-38-55</phone>
      <email>antoine.guillon@univ-tours.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Francois B, Jeannet R, Daix T, Walton AH, Shotwell MS, Unsinger J, Monneret G, Rimmelé T, Blood T, Morre M, Gregoire A, Mayo GA, Blood J, Durum SK, Sherwood ER, Hotchkiss RS. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight. 2018 Mar 8;3(5). pii: 98960. doi: 10.1172/jci.insight.98960.</citation>
    <PMID>29515037</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>January 24, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2019</study_first_posted>
  <last_update_submitted>November 6, 2019</last_update_submitted>
  <last_update_submitted_qc>November 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>IL-7</keyword>
  <keyword>lymphocytopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Study results will be published Individual data can't be shared and are protected by the new GDPR rule</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

